Impressively, the unit registered the lowest frequency loss of any chip to date. Specifically, the engineers noted that the new chip was 15x more stable and 100x more efficient in terms of microwave ...

TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads today ...

BHVN’s investment case definitely weakened after Opakalim’s Phase 2 MDD miss. This also means they’ll discontinue their ...

ITP is a rare disease of complex immune dysregulation leading to lower platelet counts, bleeding, and reduced quality of life ...

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, today ...

TAMPA, Fla. and LONDON, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology ...

“Photon Design's next-generation, EPIPPROP simulator, will offer the flexibility to split waveguides, simulating this process ...

OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral ...

Jonas Salk quietly built the polio vaccine through rigorous, methodical work in Pittsburgh: treating patients, refinin ...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in anxiety as measured by SUDS scores compared to placeboFavorable safety and tolerability data were ...

First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 Trial Builds on Recent Evidence of Persistent ...

-- First Patient Expected to be Dosed Next Week with Intranasal Foralumab -- PET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer's Patient on Leqembi (R) (Lecanemab) Anti-Amyloid ...